Considerations for the clinical development of immuno-oncology agents in cancer

Atanasio Pandiella(Complejo Hospitalario Universitario de Albacete), Alberto Ocaña(Hospital General Universitario de Albacete)
Frontiers in Immunology
August 11, 2023
10.3389/fimmu.2023.1229575
Cited by 3

Related Papers

Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks
|Blood|2008|89
Synthetic Lethality Interaction Between Aurora Kinases and CHEK1 Inhibitors in Ovarian Cancer
|Molecular Cancer Therapeutics|2017|63
Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling
|BMC Cancer|2014|58
Effect of Multikinase Inhibitors on Caspase-Independent Cell Death and DNA Damage in HER2-Overexpressing Breast Cancer Cells
|JNCI Journal of the National Cancer Institute|2010|48
Options to Improve the Action of PROTACs in Cancer: Development of Controlled Delivery Nanoparticles
|Frontiers in Cell and Developmental Biology|2022|37